Ulcerative colitis (UC) is a chronic inflammatory disease of the colonic mucosa. Infliximab has long been a standard therapy for moderate to severe UC. IV followed by oral cyclosporine (CsA) has demonstrated similar safety and efficacy to infliximab for the treatment of acute UC; however, prolonged use for the maintenance of remission is limited due to concerns about side effects of systemically available CsA. There remains a need for an oral CsA therapy that controls UC disease activity while minimizing systemic exposure.